A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open-label study and consists of 3 treatment groups (dose levels) .
Treatment cycles are 3 weeks in duration. The primary objective of this study is to determine
the recommended phase two dose (RPTD) of veliparib (ABT-888) when administered in combination
with carboplatin and paclitaxel in Japanese subjects with solid tumors. Secondary objectives
are to assess pharmacokinetics and to obtain a preliminary efficacy of anti-tumor activity in
the subjects.